People with the most common type of lung cancer, which up to a few decades ago have not survived more than two years after diagnosis, today have survived, thanks to the t immunotherapy, which successfully prevents signs of this disease in 80% of cases, recently confirmed by the Spanish oncologist Ignacio Gil Bazo.
Y National Administration of Medicines, Food and Medical Technology (Anmat) has just approved pembrolizumab (the medicine that is treating this problem) to use it in some signs of lung cancer.
The unbelievable clinical impact of immunotherapy in patients with cancer forces us to re-evaluate survival, as some sick people who have not lived more than two years now are four years or more after diagnosis, says Gil Bazo.
The specialist confirmed that he was a patient with non-small-cell lung cancer (CPCNPThey were treated with pembrolizumab, a medicine that belongs to the immunotherapies as it is called, as they help the immune system to slow down or prevent the growth of cancer cells.
Gil Bazo also noted that they saw complete pathological responses, ie, the absence of signs of cancer, in 80% of patients with this disease, and major or very important pathological responses in more than 90%, Va Passport reports.
That is why we want to bring a hopeful message to people: healing is possible and we are approaching. And while there is no certainty yet because we are studying patients, we can say that the disease has already been chronicled, he added.
Lung cancer is the most common malignant malignant tumor worldwide and one of the most fatal, especially if it is detected late.
According to data from the World Health Organization (WHO) International Agency for Cancer Research, this is the fourth largest number in our country, with 11,595 new cases diagnosed each year.